Geron Shares Fall After Disappointing 4Q, Outlook Despite Restructuring

Dow Jones
Feb 26

By Katherine Hamilton

 

Geron shares fell on disappointing fourth-quarter results and guidance, despite restructuring efforts.

The stock slid 16% to $1.65 on Wednesday. Shares are still up 3.4% over the past 12 months.

The Foster City, Calif., biopharmaceutical company posted roughly flat sales of $48.0 million, below the $50.4 million analysts were expecting.

It had an adjusted loss of 5 cents a share, while analysts had been projecting a loss of 3 cents a share.

Costs continued to rise for Geron as well. The company cut a third of its workforce in December as part of a restructuring effort. Expenses increased to $75.8 million from $67.6 million the year before.

Geron expects revenue will be $220 million to $240 million for this year, missing analysts' guidance of $242.6 million.

 

Write to Katherine Hamilton at katherine.hamilton@wsj.com

 

(END) Dow Jones Newswires

February 25, 2026 13:34 ET (18:34 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10